Find an expert

Dr Lauren Aoude is a research leader at the University of Queensland (UQ) Frazer Institute. Her research program explores barriers to precision oncology, and establishes more accurate prognostics to enhance therapeutic options for oesophageal adenocarcinoma (OAC) and melanoma patients. Her research integrates genomic sequencing data with clinical, pathological and imaging information. Recent work includes the establishment of patient-derived organoid models to enable a personalised medicine approach.

During her PhD (completed Nov 2014, QIMR Berghofer) she was a key member of international collaborations that significantly enhanced the understanding of melanoma susceptibility in at-risk families. Dr Aoude joined UQ as an NHMRC Early Career Fellow (2016-2021), where she led projects exploring precision medicine for metastatic melanoma and oesophageal cancer. In 2021, she was awarded a UQ Amplify fellowship to pursue research while expanding teaching and mentoring opportunities, including an on-going course co-ordinator role in the Master of Medicine Skin Cancer Program.

In 2025, she was awarded an NHMRC (EL2) Emerging Leader Fellowship. Her program vision is to better inform treatment decisions and improve health outcomes for patients through the integration of genomics into the clinic.

Dr Kevin M. Koo is currently a National Health and Medical Research Council (NHMRC) Investigator Fellow and Prostate Cancer Foundation of Australia (PCFA) Future Leader Fellow at The University of Queensland Centre for Clinical Research (UQCCR). Dr Koo was awarded his PhD (Dean’s Award for Outstanding Thesis) from the Australian Institute for Bioengineering & Nanotechnology (AIBN), UQ in 2018.

Post-PhD, he begun a productive postdoctoral career with dual industry/academia appointments: as the Head of Assay Development/Lab Director in XING Technologies Pty Ltd (a Brisbane-based biotech start-up) to undertake product development projects for commercialization of disease in vitro diagnostics, and as an Honorary Fellow/Principal Research Scientist at UQCCR to continue his academic research in precision cancer nanodiagnostics. His research skills and experiences are honed through dedicated career time spent in both academic research and regulated industry environments.

Dr Koo's research encompasses multi-disciplinary fields of molecular biomarker and nanobiosensor development, translation, and commercialization for precision disease management applications. Presently, he is working on the design and development of integrated multi-bioanalyte sensing technologies to resolve the various challenges around holistic disease pathway understanding and clinical biomarker profiling.

Dr Koo's research endeavours have been recognized by a Metrohm Australia-New Zealand Young Chemist Award (2018), Australian Institute of Policy & Science (AIPS) Queensland Young Tall Poppy Science Award (2023) and UQ Faculty of Medicine "Rising Star of the Year" Excellence Award (2024).

Peter Simpson is a recognised expert in the molecular and pathological characterisation of breast and lung cancers. His research is based at the UQ Centre for Clinical Research (UQCCR), where he is the Head of the Cancer Theme and is a Research Group Leader in Cancer Genomics. He has published >150 articles (>12,000 citations, H-index 52; Scopus, May2025) including in Nature, Nature Medicine, Annals of Oncology and the American Journal of Respiratory and Critical Care Medicine. He co-manages the Brisbane Breast Bank (BBB), a tissue bank created to facilitate clinical breast cancer research, and the Debutant lung cancer Program.

Pete also holds a teaching appointment in UQ, where he is passionate about the science and clinical applications of Pathology. He teaches into the UQ Medical Program (Year 1 and 2), as well as to undergraduates. He has co-authored a chapter ‘Breast Diseases’ in the latest edition (11th) of the internationally acclaimed Medical text book Robbins and Cotran Pathologic Basis of Disease.

Outside UQ, Pete is a Fellow of the Faculty of Science in the Royal College of Pathologists of Australasia (FFSc RCPA), a member of the kConFab Executive (https://www.kconfab.org/), a member of the Lobular Breast Cancer Alliance Scientific Advisory Board (https://lobularbreastcancer.org/), and a member of the International Cancer Genome Consortium (Breast Cancer group).

Pete enjoys supervising students at all levels in their careers and collaborating within multidisciplinary teams spanning clinical (e.g. pathology, oncology) and science teams (e.g. in ‘omics, bioinformatics and machine learning).